X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used in the development for ILC’s lead hybrid interferon drug, Alfacyte (human alpha interferon), an anti-viral medicine for the treatment of upper respiratory tract viral infections, including SARS-CoV-2 which causes Covid-19.
Lead Product(s): Human Alpha Interferon
Therapeutic Area: Infections and Infectious Diseases Product Name: Alfacyte
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eos Angel Investment Syndicate
Deal Size: $4.8 million Upfront Cash: Undisclosed
Deal Type: Financing April 26, 2023
Details:
ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta 1a.
Lead Product(s): IFN Alpha-14
Therapeutic Area: Infections and Infectious Diseases Product Name: Alfacyte
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The collaborative work between ILC Therapeutics and Dr. Catherine Adamson from the School of Biology at the University of St Andrews, will focus on the role that Alfacyte can play in preventing COVID-19-indusced acute respiratory distress syndrome (ARDS).
Lead Product(s): Alfacyte
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Alfacyte
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: University of St Andrews
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2020
Details:
The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.
Lead Product(s): Interferon Alpha 14
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
